The CUREator+ Dementia and Cognitive Decline incubator program is a partnership between Brandon BioCatalyst, ANDHealth and Dementia Australia.
Expressions of Interest for the CUREator+ Dementia and Cognitive Decline Incubator are now open to entrepreneurial researchers, clinical innovators, and founders across Australia.
Our first information session will be held on Wednesday 5 Jun 2024 at 12:00 pm – 1:00 pm (AEST) and registrations are now open here.
Companies that are pioneering innovative health technologies to enhance the lives of individuals affected by dementia and cognitive decline up can apply to receive up to $5 million per project in non-dilutive project funding.
Funded by the Federal Government’s $20 billion Medical Research Future Fund (MRFF), the program aims to support the development of novel approaches, spanning therapeutics, diagnostics, assistive and medical devices and digital health technologies, that will prolong or improve the lives of the estimated 421,000 Australians currently living with Dementia and the 1.6 million caregivers who support them.
The program delivers funding in tranches tied to mutually agreed-upon milestones and will leverage Australia’s globally recognised life sciences research and health technology strengths to enhance the commercialisation and translation of innovations that improve health and wellbeing.
By aligning funding incentives and progress, CUREator+ aims to cultivate a thriving local ecosystem of innovation and entrepreneurship dedicated to tackling the escalating global issue of Dementia and Cognitive Decline.
CUREator+ provides non-dilutive grant funding to projects, up to $5 million per project. The funding supports commercially orientated projects, through tranched funding dispersed upon the successful completion of key pre-agreed project milestones.
CUREator+ successful applicants will benefit from support of the CUREator+ team alongside the broader Brandon BioCatalyst and ANDHealth Teams. CUREator+ will provide successful applicants with hands-on support and access to their global network of experts.
In addition, SMEs can expect to benefit from connections to pharmaceutical companies, local and international venture capital firms and institutional investors. Through these networks, CUREator+ will assist projects and companies seeking follow-on funding. SMEs may apply for Brandon BioCatalyst for investment, and this is on an equity investment basis.
